Omeros (NASDAQ:OMER – Get Free Report) posted its earnings results on Monday. The biopharmaceutical company reported $0.06 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.04, Zacks reports.
Omeros Price Performance
Shares of OMER stock traded down $0.81 on Monday, hitting $16.68. The stock had a trading volume of 1,506,323 shares, compared to its average volume of 1,596,064. The firm has a market capitalization of $1.21 billion, a P/E ratio of 13.03 and a beta of 2.96. Omeros has a 1 year low of $6.70 and a 1 year high of $21.24. The company’s 50 day moving average price is $18.27 and its 200-day moving average price is $13.74.
Insider Transactions at Omeros
In related news, VP Peter B. Cancelmo sold 25,000 shares of Omeros stock in a transaction on Monday, August 31st. The stock was sold at an average price of $18.54, for a total value of $463,500.00. Following the completion of the transaction, the vice president directly owned 200 shares in the company, valued at approximately $3,708. This trade represents a 99.21% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CAO David J. Borges sold 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, September 23rd. The stock was sold at an average price of $20.95, for a total transaction of $209,500.00. Following the sale, the chief accounting officer owned 5,000 shares in the company, valued at $104,750. The trade was a 66.67% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 100,906 shares of company stock valued at $1,904,955. Insiders own 10.50% of the company’s stock.
Wall Street Analysts Forecast Growth
Several equities research analysts have issued reports on the company. HC Wainwright reissued a “buy” rating on shares of Omeros in a research note on Monday, July 27th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $22.00 price target on shares of Omeros in a research note on Wednesday, October 14th. Wall Street Zen upgraded Omeros from a “hold” rating to a “buy” rating in a report on Saturday, August 15th. Finally, Weiss Ratings raised Omeros from a “hold (c-)” rating to a “hold (c)” rating in a research report on Thursday, October 8th. Three equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $30.33.
View Our Latest Stock Report on OMER
Omeros Company Profile
Omeros Corporation (NASDAQ: OMER) is a biopharmaceutical company focused on discovering, developing and commercializing therapies for disorders involving the complement, immune and coagulation systems. The company has also developed a pipeline of investigational therapies aimed at treating serious diseases involving complement activation and immune-system dysfunction. The company is headquartered in Seattle, Washington, and was founded in 1994. Its leading investigational programs have included narsoplimab, which targets the lectin pathway of the complement system, and OMS906, an antibody designed to inhibit MASP-3 and regulate the alternative pathway.
Further Reading
- Five stocks we like better than Omeros
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.
